AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa

Journal of the International AIDS Society

Volumn 13, Issue 1, 2010, Pages

  Chu, Kathryn M ^a   Mahlangeni, Gcina ^a   Swannet, Sarah ^a   Ford, Nathan P ^a,b   Boulle, Andrew ^b   Van Cutsem, Gilles ^a,b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINBLASTINE; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ADVANCED CANCER; ANTIVIRAL THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; FEMALE; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR; SOUTH AFRICA; TERTIARY HEALTH CARE; AIDS RELATED COMPLEX; COHORT ANALYSIS; MIDDLE AGED; PRIMARY HEALTH CARE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RISK FACTORS; SARCOMA, KAPOSI; SOUTH AFRICA;

EID: 77957151933     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-13-23     Document Type: Article

References (17)

1. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. S Franceschi LD Maso M Rickenbach J Polesel B Hirschel M Cavassini A Bordoni L Elzi S Ess G Jundt N Mueller GM Clifford, Br J Cancer 2008 99 800 804 10.1038/sj.bjc.6604520 18665172
2. Cancer: the effects of HIV and antiretroviral therapy, and implications for early antiretroviral therapy initiation. AE Grulich, Curr Opin HIV AIDS 2009 4 183 187 10.1097/COH.0b013e328329c5b2 19532048
3. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. A Mocroft O Kirk N Clumeck P Gargalianos-Kakolyris H Trocha N Chentsova F Antunes HJ Stellbrink AN Phillips JD Lundgren, Cancer 2004 100 2644 2654 10.1002/cncr.20309 15197808
4. Cancer incidence in people with AIDS in Italy. J Polesel S Franceschi B Suligoi E Crocetti F Falcini S Guzzinati M Vercelli R Zanetti G Tagliabue A Russo S Luminari F Stracci V De Lisi S Ferretti L Mangone M Budroni RM Limina S Piffer D Serraino F Bellu A Giacomin A Donato A Madeddu S Vitarelli M Fusco R Tessandori R Tumino P Piselli L Dal Maso, Int J Cancer 2010 20049835
5. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta. S Gingues MJ Gill, HIV Med 2006 7 369 377 10.1111/j.1468-1293.2006.00395.x 16903981
6. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. HK Tam ZF Zhang LP Jacobson JB Margolick JS Chmiel C Rinaldo R Detels, Int J Cancer 2002 98 916 922 10.1002/ijc.10274 11948473
7. Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy. L Blum C Pellet F Agbalika G Blanchard P Morel F Calvo C Lebbe, AIDS 1997 11 1653 1655 9365774
8. Complete regression of AIDS-related Kaposi's sarcoma-associated human herpesvirus-8 during therapy with indinavir. C Martinelli M Zazzi S Ambu D Bartolozzi P Corsi F Leoncini, AIDS 1998 12 1717 1719 9764794
9. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. G Murdaca A Campelli M Setti F Indiveri F Puppo, AIDS 2002 16 304 305 10.1097/00002030-200201250-00029 11807324
10. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. SE Krown, J Clin Oncol 2004 22 399 402 10.1200/JCO.2004.08.064 14752065
11. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. EB El Amari L Toutous-Trellu A Gayet-Ageron M Baumann G Cathomas I Steffen P Erb NJ Mueller H Furrer M Cavassini P Vernazza HH Hirsch E Bernasconi B Hirschel, AIDS 2008 22 1019 1028 10.1097/QAD. 0b013e3282fc9c03 18520345
12. Management of AIDS-related Kaposi's sarcoma. G Di Lorenzo PA Konstantinopoulos L Pantanowitz R Di Trolio S De Placido BJ Dezube, Lancet Oncol 2007 8 167 176 10.1016/S1470-2045(07)70036-0 17267331
13. Western Cape Provincial Health Department, HIV Prevalence in the Western Cape, Cape Town 2006
14. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. SE Krown MA Testa J Huang, J Clin Oncol 1997 15 3085 3092 9294471
15. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. M Bower M Nelson AM Young C Thirlwell T Newsom-Davis S Mandalia T Dhillon P Holmes BG Gazzard J Stebbing, J Clin Oncol 2005 23 5224 5228 10.1200/JCO.2005.14.597 16051964
16. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era - the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. G Nasti R Talamini A Antinori F Martellotta G Jacchetti F Chiodo G Ballardini L Stoppini G Di Perri M Mena M Tavio E Vaccher A D'Arminio Monforte U Tirelli, J Clin Oncol 2003 21 2876 2882 10.1200/JCO.2003.10.162 12885804
17. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. MW Brinkhof M Pujades-Rodriguez M Egger, PLoS One 2009 4 5790 10.1371/journal. pone.0005790 19495419